Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

0.5649
+0.00811.45%
Volume:184.84K
Turnover:101.13K
Market Cap:18.93M
PE:-0.54
High:0.5729
Open:0.5729
Low:0.5100
Close:0.5568
Loading ...

BRIEF-Rani Therapeutics Q1 Net Income USD -12.738 Million

Reuters
·
14 May

Rani Therapeutics Hldgs Q1 EPS $(0.22) Misses $(0.21) Estimate, Sales $172.00K

Benzinga
·
14 May

Press Release: Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Dow Jones
·
14 May

Rani Therapeutics Faces Nasdaq Compliance Challenge

TIPRANKS
·
07 May

Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Rani Therapeutics Holdings: Buy Rating Backed by Strong Financial Position and Promising Clinical Trials

TIPRANKS
·
03 Apr

RANI: 2024 Financial Results

Zacks Small Cap Research
·
01 Apr

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

TIPRANKS
·
01 Apr

Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com
·
01 Apr

BRIEF-Rani Therapeutics Q4 Operating Expenses USD 15.986 Million

Reuters
·
01 Apr

Rani Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate

Benzinga
·
01 Apr

Rani Therapeutics Q4 Operating Expenses USD 15.986 Million

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings Inc Q4 Shr View $-0.25 -- Lseg Ibes Data

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings Inc Q4 Shr Loss $0.27

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings: Cash, Cash Equivalents & Marketable Securities Sufficient to Fund Ops Into Q3

THOMSON REUTERS
·
01 Apr

Press Release: Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Dow Jones
·
01 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102

Reuters
·
27 Mar